# Bayer HealthCare

K110587 MAR 2 8 2012A 141 ER

# 510(k) SUMMARY

Summary of \$10(k) safety and effectiveness in accordance with the requirements of 21 . CFR 807.92.

<table><tr><td>Submitt</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>Bayer Healthcare</td></tr><tr><td rowspan=1 colspan=1>Address</td><td rowspan=1 colspan=1>555 White Plains RoadTarrytown, NY 10591</td></tr><tr><td rowspan=1 colspan=1>Phone number</td><td rowspan=1 colspan=1>(914) 366-1800</td></tr><tr><td rowspan=1 colspan=1>Fax number</td><td rowspan=1 colspan=1>(914) 366-1899</td></tr><tr><td rowspan=1 colspan=1>EstablishmentRegistrationNumber</td><td rowspan=1 colspan=1>3003962513</td></tr><tr><td rowspan=1 colspan=1>Name of contactperson</td><td rowspan=1 colspan=1>Chuck Ryan</td></tr><tr><td rowspan=1 colspan=1>Date prepared</td><td rowspan=1 colspan=1>March 27, 2012</td></tr></table>

Name of device

<table><tr><td rowspan=1 colspan=1>Trade or proprietaryname</td><td rowspan=1 colspan=1>CONTOUR® LINK</td></tr><tr><td rowspan=1 colspan=1>Common or usualname</td><td rowspan=1 colspan=1>Wireless Blood Glucose Monitoring System</td></tr><tr><td rowspan=1 colspan=1>Classification name</td><td rowspan=1 colspan=1>Glucose Test System</td></tr><tr><td rowspan=1 colspan=1>Classification panel</td><td rowspan=1 colspan=1>Clinical Chemistry and Clinical Toxicology</td></tr><tr><td rowspan=1 colspan=1>Regulation</td><td rowspan=1 colspan=1>21 CFR 862.1345</td></tr><tr><td rowspan=1 colspan=1>Product Code(s)</td><td rowspan=1 colspan=1>LFR (Glucose Dehydrogenase, Glucose), NBW (System,Test, Blood Glucose, Over The Counter)</td></tr><tr><td rowspan=1 colspan=1>Legally marketeddevice(s) to whichequivalence is claimed</td><td rowspan=1 colspan=1>CONTOUR Blood Glucose Meter (K062058)OneTouch UltraLink Blood Glucose Meter (K073231)</td></tr><tr><td rowspan=1 colspan=1>Reason for 510(k)submission</td><td rowspan=1 colspan=1>Addition of RF wireless transmission capability</td></tr><tr><td rowspan=1 colspan=1>Device description</td><td rowspan=1 colspan=1>The CONTOUR LINK Wireless Blood GlucoseMonitoring System features the CONTOUR LINKWireless Blood Glucose Monitor and the currentlymarketed CONTOUR Blood Glucose Test Strips, amongother components (e.g., lancing device, lancets andcontrol solution)</td></tr></table>

# Bayer HealthCare

<table><tr><td>Intended use of the device Indications for use</td><td>See Indications for Use below The CONTOUR® LINK Wireless Blood Glucose</td></tr><tr><td></td><td>Monitoring System is an over the counter (OTC) device utilized by persons with diabetes in home settings for the measurement of glucose in whole blood, and is for single-patient use only and should not be shared. The CONTOUR® LINK Wireless Blood Glucose Monitoring System is indicated for use with fresh capillary whole blood samples drawn from the fingertip only.</td></tr><tr><td rowspan="2"></td><td>CONTOUR® test strips are intended for self-testing by persons with diabetes for the quantitative measurement of glucose in whole blood samples from 20 to 600 mg/dL.</td></tr><tr><td>The CONTOUR® LINK Wireless Blood Glucose Monitoring System is intended to be used to transmit glucose values to Medtronic MiniMed Paradigm Insulin Pumps or Medtronic MiniMed Paradigm REAL-Time Revel Insulin Pumps through use of radio frequency communication.</td></tr></table>

SIMILARITIES to Predicate 1   

<table><tr><td>Summary of the Technological Characteristics of the New Device Compared to wcn 1F redicate:</td></tr></table>

Page 2 of 10   

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>New DeviceBayer&#x27;s CONTOUR LINKmeter</td><td rowspan=1 colspan=1>Predicate 1Bayer&#x27;s CONTOUR meterK062058</td></tr><tr><td rowspan=1 colspan=1>DetectionTechnology</td><td rowspan=1 colspan=1>Amperometric measurement ofblood glucose</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Reference method</td><td rowspan=1 colspan=1>Plasma equivalent</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Test strip</td><td rowspan=1 colspan=1>CONTOUR test strip</td><td rowspan=1 colspan=1>same</td></tr></table>

# Bayer HealthCare

<table><tr><td></td><td rowspan=1 colspan=1>Test Strip enzyme</td><td rowspan=1 colspan=1>Glucose Dehydrogenase FAD</td><td rowspan=1 colspan=1>same</td></tr><tr><td></td><td rowspan=1 colspan=1>Calibration/Coding</td><td rowspan=1 colspan=1>No coding needed</td><td rowspan=1 colspan=1>same</td></tr><tr><td></td><td rowspan=1 colspan=1>Accuracy</td><td rowspan=1 colspan=1>Meets ISO 15197 requirements</td><td rowspan=1 colspan=1>same</td></tr><tr><td></td><td rowspan=1 colspan=1>Reaction time</td><td rowspan=1 colspan=1>5 seconds</td><td rowspan=1 colspan=1>same</td></tr><tr><td></td><td rowspan=1 colspan=3>DIFFERENCES from Predicate 1</td></tr><tr><td></td><td rowspan=1 colspan=1>RFCommunicationProtocol</td><td rowspan=1 colspan=1>Transmits glucose values tocompatible MiniMed Paradigmand Guardian REAL Timedevices.</td><td rowspan=1 colspan=1>No RF capability</td></tr><tr><td></td><td rowspan=1 colspan=1>Alternative sitetesting</td><td rowspan=1 colspan=1>Fingertip only</td><td rowspan=1 colspan=1>Fingertip, palm or forearm</td></tr><tr><td></td><td rowspan=1 colspan=1>Measurementrange</td><td rowspan=1 colspan=1>20-600 mg/dL</td><td rowspan=1 colspan=1>10-600 mg/dL</td></tr><tr><td></td><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>Capillary whole blood samplesonly. Not for use on neonates.</td><td rowspan=1 colspan=1>Capillary, venous, andarterial whole bloodsamples and neonatal bloodsamples</td></tr><tr><td></td><td rowspan=1 colspan=1>Hct range</td><td rowspan=1 colspan=1>20-65%</td><td rowspan=1 colspan=1>0-70%</td></tr><tr><td></td><td rowspan=1 colspan=3>Summary of the Technological Characteristics of the New Device Compared toPredicate 2</td></tr><tr><td></td><td rowspan=1 colspan=3>SIMILARITIES to Predicate 2</td></tr><tr><td rowspan=1 colspan=2>Characteristic</td><td rowspan=1 colspan=1>New DeviceBayer&#x27;s CONTOUR LINKmeter</td><td rowspan=1 colspan=1>Predicate 2LifeScan OneTouchUltraLink meterK073231</td></tr><tr><td rowspan=1 colspan=2>DetectionTechnology</td><td rowspan=1 colspan=1>Amperometric measurement ofblood glucose</td><td rowspan=1 colspan=1>same</td></tr></table>

# Bayer HealthCare

<table><tr><td rowspan=8 colspan=7>Reference method Plasma equivalent                        sameAccuracy              Meets ISO 15197 requirements      sameSample type          Capillary whole blood samples       sameonly. Not for use on neonates.Reaction time        5 seconds                                   sameMeasurement         20-600 mg/dL                             samerangeRF                       Transmits glucose values to           sameCommunication     compatible Medtronic MiniMedProtocol               devices.DIFFERENCES from Predicate 2</td></tr><tr><td rowspan=1 colspan=2>Reference method</td><td rowspan=1 colspan=2>Plasma equivalent</td><td rowspan=1 colspan=2>same</td></tr><tr><td rowspan=1 colspan=2>Accuracy</td><td rowspan=1 colspan=2>Meets ISO 15197 requirements</td><td rowspan=1 colspan=2>same</td></tr><tr><td rowspan=1 colspan=2>Sample type</td><td rowspan=1 colspan=2>Capillary whole blood samplesonly. Not for use on neonates.</td><td rowspan=1 colspan=2>same</td></tr><tr><td rowspan=1 colspan=2>Reaction time</td><td rowspan=1 colspan=2>5 seconds</td><td rowspan=1 colspan=2>same</td></tr><tr><td rowspan=1 colspan=2>Measurementrange</td><td rowspan=1 colspan=2>20-600 mg/dL</td><td rowspan=1 colspan=2>same</td></tr><tr><td rowspan=1 colspan=2>RFCommunicationProtocol</td><td rowspan=1 colspan=2>Transmits glucose values tocompatible Medtronic MiniMeddevices.</td><td rowspan=1 colspan=2>same</td></tr><tr><td rowspan=1 colspan=6>DIFFERENCES from Predicate 2</td></tr><tr><td rowspan=1 colspan=2>Test Strip</td><td></td><td rowspan=1 colspan=2>CONTOUR test strip</td><td rowspan=1 colspan=2>OneTouch Ultra test strip</td></tr><tr><td rowspan=1 colspan=2>Test Strip enzyme</td><td rowspan=1 colspan=2>Glucose Dehydrogenase FAD</td><td rowspan=1 colspan=2>Glucose Oxidase</td><td></td></tr><tr><td rowspan=1 colspan=2>Alternative sitetesting</td><td rowspan=1 colspan=2>Fingertip only</td><td rowspan=1 colspan=2>Fingertip, palm or forearm</td><td></td></tr><tr><td rowspan=1 colspan=2>Calibration/Coding</td><td rowspan=1 colspan=2>No coding needed</td><td rowspan=1 colspan=2>Manual coding required</td><td></td></tr><tr><td rowspan=1 colspan=2>Hct range</td><td rowspan=1 colspan=2>20-65%</td><td rowspan=1 colspan=2>30-55%</td><td></td></tr><tr><td rowspan=1 colspan=6>PERFORMANCE DATA</td><td></td></tr><tr><td rowspan=1 colspan=6>SUMMARY OF NON-CLINICAL TESTS CONDUCTED FORDETERMINATION OF SUBSTANTIAL EQUIVALENCE</td><td></td></tr><tr><td rowspan=1 colspan=6>Performance Test Summary-New Device</td><td></td></tr><tr><td rowspan=1 colspan=2>Characteristic</td><td rowspan=1 colspan=4>Results Summary</td><td></td></tr></table>

# Bayer HealthCare

<table><tr><td>Precision</td><td>Repeatability (ISO 15197 Section 7.2.2) Reference: 510(k) submission, Section 018-4 Protocol: Venous blood was tested at five glucose concentration ranges: 30  50, 51  110, 111. 150, 151  250 and 251 - 400mg/dL. One lot of test strips was tested on 10 meters with 10 replicates per meter (n=100). Acceptance criteria: No ISO acceptance criteria stated. Internal acceptance criteria: Repeatability test must perform within the established accuracy requirements. (Cpk values &gt; 1.0 when compared to established accuracy requirements of ± 20% or ± 15mg/dL.). Results: Cpk values are greater than 1.0 when compared to established accuracy requirements of ± 20% or ± 15mg/dL.</td></tr></table>

Mean, SD and $\% C V$ were as follows:   

<table><tr><td rowspan=1 colspan=1>Mean, mg/dL</td><td rowspan=1 colspan=1>SD,mg/dL</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>41.8</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>3.02%</td></tr><tr><td rowspan=1 colspan=1>78.1</td><td rowspan=1 colspan=1>1.99</td><td rowspan=1 colspan=1>2.55%</td></tr><tr><td rowspan=1 colspan=1>125.7</td><td rowspan=1 colspan=1>2.67</td><td rowspan=1 colspan=1>2.12%</td></tr><tr><td rowspan=1 colspan=1>198.0</td><td rowspan=1 colspan=1>4.32</td><td rowspan=1 colspan=1>2.18%</td></tr><tr><td rowspan=1 colspan=1>312.3</td><td rowspan=1 colspan=1>5.01</td><td rowspan=1 colspan=1>1.60%</td></tr></table>

Intermediate Precision (ISO 15197 Section 7.2.3) Reference: $\pmb { 5 1 0 ( \mathrm { l t } ) }$ submission, Section 018-4

Protocol: Three levels of control solutions (Low, Normal and High) were tested on 10 meters over the course of 10 days. One measurement was taken per meter per lot per control solution per day.

Acceptance criteria: Cp value for 10 days> 1.0 when compared to established limits of $+ 1 1 \%$ or $+ 5 \mathrm { m g / d L }$ .

Results: Cp values are over 1.0 when compared to established limits $\mathbf { o f } + 1 1 \% \mathbf { o f } + 5 \mathbf { m } \mathbf { g } / \mathrm { d L }$ .

Mean, SD and $\% C V$ were as follows:   

<table><tr><td rowspan=1 colspan=1>ControlLevel</td><td rowspan=1 colspan=1>Mean,mg/dL</td><td rowspan=1 colspan=1>SD,mg/dL</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>38.9</td><td rowspan=1 colspan=1>0.55</td><td rowspan=1 colspan=1>1.41</td></tr><tr><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>121.7</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>1.04</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>354.9</td><td rowspan=1 colspan=1>4.49</td><td rowspan=1 colspan=1>1.26</td></tr></table>

# Bayer HealthCare

<table><tr><td rowspan=2 colspan=5>Accuracy              System Accuracy Evaluation (ISO 15197 Section 7.3)Reference: 510(k) submission, Section 018-5Protocol: Fresh capillary blood was collected in the glucoserange distribution specified by ISO 15197 Section 7.3. Onehundred blood samples were tested using each of two CONTOURtest strip lots on two CONTOUR LINK meters for a total of 400readings. Samples were also tested in parallel on a YSI 2300STAT PLUS glucose analyzer.Acceptance Criteria: A minimum of 95 % of the individualglucose results shall fall within ± 15 mg/dL of the resultsobtained on the YSI analyzer at glucose concentrations &lt; 75mg/dL, and within ± 20 % at glucose concentrations ≥75 mg/dL.Results: 98.7 % of the individual glucose results fell within ± 15mg/dL of the results obtained on the YSI analyzer at glucoseconcentrations &lt; 75 mg/dL. 98.5% fell within ± 20 % at glucoseconcentrations ≥75 mg/dL.</td></tr><tr><td rowspan=1 colspan=1>Accuracy</td><td rowspan=1 colspan=4>System Accuracy Evaluation (ISO 15197 Section 7.3)Reference: 510(k) submission, Section 018-5Protocol: Fresh capillary blood was collected in the glucoserange distribution specified by ISO 15197 Section 7.3. Onehundred blood samples were tested using each of two CONTOURtest strip lots on two CONTOUR LINK meters for a total of 400readings. Samples were also tested in parallel on a YSI 2300STAT PLUS glucose analyzer.Acceptance Criteria: A minimum of 95 % of the individualglucose results shall fall within ± 15 mg/dL of the resultsobtained on the YSI analyzer at glucose concentrations &lt; 75mg/dL, and within ± 20 % at glucose concentrations ≥75 mg/dL.Results: 98.7 % of the individual glucose results fell within ± 15mg/dL of the results obtained on the YSI analyzer at glucoseconcentrations &lt; 75 mg/dL. 98.5% fell within ± 20 % at glucoseconcentrations ≥75 mg/dL.</td></tr><tr><td rowspan=7 colspan=1>Linearity/assayreportable range</td><td rowspan=1 colspan=4>Established in predicate submission (k062058).Reference: 510(k) submission, Section 018-7Two studies were conducted to establish the linearity of theCONTOUR system throughout the entire reportable range of 10 to600 mg/dL. In one study, blood with a hematocrit level of 40% wasadjusted to plasma glucose concentrations of 20, 30, 40, 50, and 60mg/dL and tested with three CONTOUR lots, 24 sensors per lot. Allresults fell within ±10mg/dL of the YSI reference value, satisfyingthe acceptance criteria.</td></tr><tr><td rowspan=1 colspan=1>Reference Level,mg/dL</td><td rowspan=1 colspan=1>Mean,mg/dL</td><td rowspan=1 colspan=1>Bias,mg/dL</td><td rowspan=1 colspan=1>CV, %</td></tr><tr><td rowspan=1 colspan=1>29.5</td><td rowspan=1 colspan=1>25.5</td><td rowspan=1 colspan=1>-4.0</td><td rowspan=1 colspan=1>3.2</td></tr><tr><td rowspan=1 colspan=1>40.6</td><td rowspan=1 colspan=1>35.3</td><td rowspan=1 colspan=1>-5.3</td><td rowspan=1 colspan=1>4.2</td></tr><tr><td rowspan=1 colspan=1>50.6</td><td rowspan=1 colspan=1>45.5</td><td rowspan=1 colspan=1>-5.0</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>60.3</td><td rowspan=1 colspan=1>54.4</td><td rowspan=1 colspan=1>-5.9</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=4>Reference: 510(k) submission, Section 018-6An additional study using three pilot production sensor lots testedsensor response across eight plasma glucose concentrations.</td></tr></table>

# Bayer HealthCare

<table><tr><td rowspan="13"></td><td colspan="4">Eight meters were used, with three sensors per lot tested on each. All results fell within ±20% at glucose level of 75 mg/dL and above, and within ±15 mg/dL at glucose level below 75 mg/dL. This met the acceptance criteria.</td></tr><tr><td>Reference Level, mg/dL</td><td>Mean, mg/dL</td><td>Bias</td><td>CV, %</td></tr><tr><td>26.4 51.1</td><td>25.8</td><td>-0.5 mg/dL</td><td>3.5</td></tr><tr><td></td><td>47.2</td><td>-3.9 mg/dL</td><td>2.2</td></tr><tr><td>77.6</td><td>74.8</td><td>-3.5%</td><td>2.1</td></tr><tr><td>118.1</td><td>115.2</td><td>-2.5%</td><td>2.7</td></tr><tr><td>195.8</td><td>194.7</td><td>-0.5%</td><td>2.3</td></tr><tr><td>300.0</td><td>304.9</td><td>1.6%</td><td>2.3</td></tr><tr><td>394.5</td><td>398.3</td><td>1.0%</td><td>1.5</td></tr><tr><td>Traceability traceable to the hexokinase method developed collaboratively by</td><td>551.0 The Yellow Springs Instruments Stat Plus 2300 analyzer (YSI) is</td><td>530.5</td><td>-3.7% 1.7</td></tr><tr><td>control. Detection limit</td><td colspan="3">the FDA, CDC, NIST and AACC. The hexokinase method is incorporated in a Bayer procedure that utilizes NIST Standard Reference Material 917, dry D-glucose. Glucose serum controls from an outside supplier were characterized by Bayer using the hexokinase method as a reference. For each day that Bayer&#x27;s YSI instruments were used as the reference method, the serum controls were analyzed to ensure that the instruments were in Established in predicate submission (k062058) as 10-600 mg/dL;</td></tr><tr><td></td><td colspan="3">stated in CONTOUR LINK specifications as 20-600 mg/dL due to absence of neonatal claim. Reference: 510(k) submission, Section 018-7 The low glucose concentration testing conducted as part of the Linearity/Assay Reportable Range above confirmed detection limit. In addition, three production lots of CONTOUR sensors were tested with whole blood samples manipulated to have glucose concentrations of 5, 900, 1200, 1500 and 1800 mg/dL, 24 sensors per samples. All readings of the 5 mg/dL samples displayed &quot;Lo&quot; and all readings of 900 mg/dL or greater</td></tr><tr><td>Analytical</td><td colspan="3">displayed &quot;Hi&quot; Reference: 510(k) submission, Section 018-8; Response to</td></tr></table>

# Bayer HealthCare

<table><tr><td rowspan=9 colspan=1>specificity</td><td rowspan=1 colspan=4>First Additional Information RequestThe interference effects of several substances were evaluated perthe table below.</td><td></td></tr><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>AddedAmount</td><td rowspan=1 colspan=1>Signal ChangeCriterion at 80 and300 mg/dL glucose</td><td rowspan=1 colspan=1>Result</td><td></td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>&gt;20 mg/dL</td><td rowspan=1 colspan=1>≤10%</td><td rowspan=1 colspan=1>Passed</td><td></td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>&gt;22 mg/dL</td><td rowspan=1 colspan=1>≤10%</td><td rowspan=1 colspan=1>Passed</td><td></td></tr><tr><td rowspan=1 colspan=1>Uric Acid</td><td rowspan=1 colspan=1>&gt;18 mg/dL</td><td rowspan=1 colspan=1>≤10%</td><td rowspan=1 colspan=1>Passed</td><td></td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>&gt;30 mg/dL</td><td rowspan=1 colspan=1>≤10%</td><td rowspan=1 colspan=1>Passed</td><td></td></tr><tr><td rowspan=1 colspan=1>Maltose</td><td rowspan=1 colspan=1>&gt;200mg/dL</td><td rowspan=1 colspan=1>&lt;7%</td><td rowspan=1 colspan=1>Passed</td><td></td></tr><tr><td rowspan=1 colspan=1>Galactose</td><td rowspan=1 colspan=1>&gt;200mg/dL</td><td rowspan=1 colspan=1>≤7%</td><td rowspan=1 colspan=1>Passed</td><td></td></tr><tr><td rowspan=1 colspan=1>Xylose</td><td rowspan=1 colspan=3>Interferes with test</td><td></td></tr><tr><td rowspan=1 colspan=1>Assay cut-off</td><td rowspan=1 colspan=4>Not applicable</td><td></td></tr><tr><td rowspan=1 colspan=5>COMPARATIVE PERFORMANCE INFORMATION SUMMARY</td><td></td></tr><tr><td rowspan=1 colspan=1>Methodcomparison withpredicate device(k062058)</td><td rowspan=1 colspan=5>Reference: 510(k) submission, Section 018-3Protocol: The CONTOUR and CONTOUR LINK meters weretested in a comprehensive fingerstick study using fresh capillaryblood samples. In this study, the RF function of the CONTOURLINK was left on to simulate real-world usage.Materials and MethodSamples from 111 subjects were collected by fingerstick andtested using two lots of CONTOUR sensors. Four CONTOURmeters were used, with disinfection between each subject.Plasma samples were tested in duplicate on the YSI referencemethod, with the average value used for the comparison.Hematocrit values also were measured. All measurements wereperformed at 23° ± 5°C.In most cases, samples were tested fresh from the finger withoutany modification. However, samples at very low and very. highglucose concentrations were created by either glycolyzing aspecimen to lower the glucose concentration or supplementing aspecimen with a concentrated glucose solution to increase theglucose level.Acceptance Criteria:</td></tr></table>

# Bayer HealthCare

<table><tr><td></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>A proportionally weighted Deming regression of the CONTOURsensor data was used to calculate slope, intercept, and the 95%confidence interval around the slope and intercept estimates shallinclude a 1.0 and 0.0, respectively.Results:A total of 444 paired readings were collected. The plasmaglucose range was 23 to 468 mg/dL, and the hematocrit rangewas 25% to 51.5%. A proportionally weighted Demingregression model was used to calculate slope and interceptestimates. The system performance meets the acceptance criteria.Slope: 0.989, confidence interval = 0.989 to 1.008Intercept: 0.49, confidence interval = -0.4 to 1.38 mg/dL</td></tr><tr><td></td><td rowspan=1 colspan=1>Linearity/assayreportable range -comparison withpredicate device(k062058)</td><td rowspan=1 colspan=1>Reference: 510(k) submission, Section 018-2Protocol: Pooled fresh venous blood at plasma glucoseconcentrations of approximately 10, 45, 67, 134, 336, and 600mg/dL were tested on eight CONTOUR LINK meters and eightCONTOUR meters with one lot of test strips. Each sample wastested three times on each meter, and a total of 24 readings werecollected per system.Acceptance criteria:95% confidence interval width for the percent differencebetween CONTOUR LINK mean and CONTOUR meanis within ± 4% (± 3 mg/dL if glucose &lt;75mg/dL) andincludes ±1% (or ±0.75mg/dL).Imprecision of the CONTOUR® LINK system is notsignificantly larger (a = 0.05) than imprecision of the 5-second CONTOUR system or Cpk values are greater than1.33.Results: Bias of the CONTOUR LINK system is not significantlylarger than bias of the predicate CONTOUR system (k062058)</td></tr><tr><td rowspan=1 colspan=3>SUMMARY OF CLINICAL TESTS CONDUCTED FOR DETERMINATIONOF SUBSTANTIAL EQUIVALENCE AND/OR OF CLINICALINFORMATION</td></tr><tr><td rowspan=1 colspan=2>Clinical study</td><td rowspan=1 colspan=1>Reference: 510(k) submission, Section 020,Protocol: The subject pool included 77 adults aged 20 through 85,each diagnosed with diabetes. The ability to follow instructions</td></tr></table>

# Bayer HealthCare

<table><tr><td>equivalent to the performance of the previously cleared CONTOUR® Blood</td><td>assessed. Results: Statistical analysis of the data indicates that the probability exceeds 95% that a randomly selected person will successfully perform any of the tasks required for successful execution of the blood glucose testing procedure. The accuracy study component of the protocol demonstrated that 95.5% of self-test results and 99.4% of HCP-test results satisfy ISO 15197 accuracy specifications (at least 95% of results must be within ±15 mg/dL at &lt;75 mg/dL and ±20% at &gt;75 mg/dL). All control solution test performed by subjects (77) generated in- range glucose values, and all were marked as controls by the meters. Reference: Predicate 510(k) K062058 Protocol: The subject device is equivalent to the predicate CONTOUR® device with RF transmission capability added. The subject pool included 109 adults aged 20 through 75, each diagnosed with diabetes. The ability to follow instructions for use for self-testing, and the resulting accuracy of results, were</td></tr><tr><td>Results:</td><td>assessed. Ninety-nine percent of the subjects either did not require any assistance or required answers to questions in an interaction that was comparable to a Customer Service call. Analytical accuracy of the subjects&#x27; self-testing was statistically indistinguishable from the laboratory glucose method. More than 96% were within the limits of ±15 mg/dL or ±20% of the laboratory glucose method, thus meeting the established performance criteria.</td></tr><tr><td colspan="2">CONCLUSIONS DRAWN FROMNON-CLINICAL AND CEINICAL DATA The performance of the CONTOUR® LINK Blood Glucose Monitoring System is</td></tr></table>

Bayer HealthCare LLC, Diabetes Care   
c/o Charles Ryan   
777 Old Saw Mill River Road   
Tarrytown, NY 10591

# MAR 2 8 2012

Re: k110587 Trade Name: CONTOUR $\dot { \bigotimes }$ Link Wireless Blood Glucose Monitoring System Regulation Number: 21 CFR $\ S 8 6 2 . 1 3 4 5$ Regulation Name: Glucose Test System Regulatory Class: Class II Product Codes: LFR, NBW Dated: March 27, 2012 Received: March 28, 2012

Dear Mr. Ryan:

We have reviewed your Section ${ \mathfrak { s l } } 0 ( { \mathfrak { k } } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

2

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number K110587:

Device Name: CONTOUR® LINK Wireless Blood Glucose Monitoring System

Indications for Use:

The CONTOUR® LINK Wireless Blood Glucose Monitoring System is an over the counter (OTC) device utilized by persons with diabetes in home settings for the measurement of glucose in whole blood, and is for single-patient use only and should not be shared. The CONTOUR® LINK Wireless Blood Glucose Monitoring System is indicated for use with fresh capillary whole blood samples drawn from the fingertip only.

CONTOUR® test strips are intended for self-testing by persons with diabetes for the quantitative measurement of glucose in whole blood samples from 20 to $6 0 0 ~ \mathrm { m g / d L }$ .

The CONTOUR $\otimes$ LINK Wireless Blood Glucose Monitoring System is intended to be used to transmit glucose values to Medtronic MiniMed Paradigm Insulin Pumps or Medtronic MiniMed Paradigm REAL-Time Revel Insulin Pumps through use of radio frequency communication.

The CONTOUR® LINK Wireless Blood Glucose Monitoring System is not intended for the diagnosis of or screening for diabetes mellitus and is not intended for use on neonates.

Prescription Use_X (21 CFR Part 801 Subpart D)

And/Or

Over the Counter Use _X (21 CFR Part 801 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/35bf9eb83507d16641ce9fc621c7375778eb64bad9b3d819a29e732138d84021.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety